News for Novartis AG (NVSN.MX)

Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Novartis (NVS) has revealed encouraging interim results from the Phase III PSMAddition trial. The study achieved its primary goal, demonstrating a statistically

Novartis (NVS) has unveiled new findings from a subgroup analysis of its Phase III NATALEE trial, which assessed the effectiveness and safety of Kisqali combine

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund returned -3.35% compared to -1.32% for the MSCI ACWI Net Index. Stock selection in consumer staples, communication services, and healthcare sectors, and allocations to […]

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of

Incyte and Novartis settle Jakafi royalty dispute with a $280M payment and future royalty rate cuts. Read more here.

GSK Plc agreed to buy an experimental medicine to treat liver disease for as much as $2 billion as the UK drugmaker seeks to shore up its pipeline of new medicines. The treatment developed by Boston Pharmaceuticals is ready to enter the last stage of clinical trials, GSK said Wednesday. The drug may have blockbuster potential, according to Bloomberg Intelligence’s John Murphy.

In a move to ensure continuous access to vital treatments, Novartis (NVS) pledged to maintain its production of medicines for malaria and leprosy, despite poten

**media[619369]**

PR NewswireNEW YORK, May 6, 2025 NEW YORK, May 6, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) â\u0080\u0093 BioNTech SE ( BNTX, â\u0080\u009cBioNTechâ\u0080\u009d or â\u0080\u009cthe Companyâ\u0080\u009d) announced today that the Supervisory Board has appoint

\n BioNTech appoints a new CFO, boosting confidence in future financial management. Analysts predict a significant upside for BioNTech's stock price. Mi

\n BioNTech (BNTX) appoints Ramón Zapata-Gomez as CFO effective July 1, 2025. Current CFO Jens Holstein will retire on June 30, 2025, as planned. Zapat

\n Novartis Expands: Significant acquisition of Regulus Therapeutics to enhance therapeutic capabilities. Analyst Insights: Average price target suggests a

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.

PR NewswireNEW YORK, May 1, 2025 NEW YORK, May 1, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fir

Novartis (NVS) plans to acquire Regulus Therapeutics to bolster its kidney disease treatments. Analysts set an average one-year price target for Novarti